


## **Global Customized Solution Provider**

10 August 2004 | News



Rank 18.....Syngene International

Revenue: 38.48 crore

**Global Customized Solution Provider** 

Syngene International, a subsidiary of Biocon established in 1994, offers customized R&D services to the pharma and biotech companies. It was the first integrated contract research organization in India in drug discovery with multidisciplinary skills in synthetic chemistry and molecular biology. It specializes in early stage drug discovery and development.

The company's sales in 2003-04, which comprises of custom research services and het sales of compounds, grew by over 46 percent from Rs 26.50 crore in 2002-03 to Rs 38.48 crore in the last fiscal. Its contracts are largely based on time and material measurements. The growth in 2003-04 has been on account of increase in the number of clients and higher realization per scientist. The company has enrolled six of the 10 major global pharma companies as its clients. In 2003-04, it added a temperature of the company has and Australia, thus expanding its existing base from those in the US and Europe.

Sytugetle sees a 1894 ifficant growth opportunity in the services sector in the future. In light of this, the company is expanding its facilities and human resources. Its new R&D facility is expected to be operation in the second half of the calendar year. This 30,000-sit facility will house research laboratories, a cGMP pilot plant for the production of Phase-I drug molecules and intermediates besides a well-equipped analytical facility complete with GC-MS, NMR and FTIR facilities. It is being readied to Address: 20th KM Hosur Road, Electronic City, Bangalore a 560 100 cater to its growing global clientele. Syngene has invested close to Rs 23.52 crore in 2003-03 on R&D, infrastructure and people 1-80-28523423

Meanwhile, in 2003-04, it registered a 52 percent growth in its staff size. In 2003-04, Syngene had 277 people, up from 182 people in 2002-03. Currently, nine percent of its staff hold PhDs and this number in 2004-05 is expected to grow to about 10.5 percent. A majority of its employees are either MSc or Mphil degree holders. This number accounts for 74 percent of the otal staff. While this group is expected to grow to 245 in FY 2005, the total number of employees would go up to 335. The growth has been on account of a 13-fold increase in its custom synthesis projects.

Syngene's strengths liever the areasest molecular biology, synthetic chemistry, and informatics. In the synthetic chemistry arena, it offers low temperature chemistry services, metal mediated synthesis, asymmetric synthesis, biotransformations, parallel synthesis Rehiral resolutions of complysis, microwave chemistry, hydrogenation under high pressure and temperature, process development and product development under cGMP.

peast, fungi, insect and mammalian cells, downstream processing and purification of recombinant proteins, customized construction of gDNA, cDNA, BAC libraries from varied sources, directed evolution and site-directed mutagenesis of proteins and 252 period of the combination of strains for improved productivity.

Year	Employees
2003-04	265
2002-03	172